Treatment of corneal neovascularization
AssigneeIrbm - Science Park S.P.A.
InventorGiulio FERRARI
Life of this patent
Estimating the term…
Abstract
There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.
Claims9
A method of preventing corneal neovascularization (“CNV”) which comprises administering to a subject in need thereof a therapeutically effective amount of an NK-1 antagonist selected from the group consisting of fosaprepitant, aprepitant, lanepitant and befetupitant and pharmaceutically acceptable salts of any one thereof, wherein the NK-1 antagonist is administered topically to the cornea.
Dependencies are inferred from the claim text.